ESC 365 - MACROS-2: RCT of ESC 0/1 versus 0/3 hour ADP for suspected ACS

ESC2025 Premium Access

MACROS-2: RCT of ESC 0/1 versus 0/3 hour ADP for suspected ACS

Session: Late-Breaking Clinical Trials: coronary artery disease and interventions

Topic: Biomarkers

Speaker: Doctor J. Hatherley (Liverpool, GB)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor James Hatherley

Liverpool University Hospitals NHS Trust, Liverpool (United Kingdom of Great Britain & Northern Ireland)

1 presentation

0 follower

3 more presentations in this session

Complete revascularisation versus usual care in non-STEMI with multivessel disease: results from the SLIM study

Speaker: Mr T. Pustjens (Maastricht, NL)

PANTHER - P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease

Speaker: Professor M. Valgimigli (Lugano, CH)

PIONEER IV trial primary report

Speaker: Professor P. Serruys (Galway, IE)

Access the full session

Late-Breaking Clinical Trials: coronary artery disease and interventions

Speakers: Doctor J. Hatherley, Mr T. Pustjens, Professor M. Valgimigli, Professor P. Serruys

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources